Unlike antibodies, CLP002’s low molecular weight enhances tumour penetration while minimising off-target effects in PD-L1-expressing healthy tissues (e.g., heart and lungs), thereby reducing immune-related adverse events (irAE) risks [142]. The gene discussed is CD274; the disease is neoplasm.